This document offers practical guidance for EU/EEA Member States on implementing genomic SARS-CoV-2 surveillance. It also includes advice on how to estimate the number of sequenced samples needed to achieve various objectives, including the early detection of novel variants.
Several SARS-CoV-2 variants have been identified. Some of these variants have mutations that (alone or in combination) may provide the virus with a selective advantage, such as increased transmissibility or the ability to evade the host immune response, or cause possible changes in pathogenicity, thus increasing disease severity.
This document outlines the use of saliva as a diagnostic sample for detecting SARS-CoV-2 infection, considering the advantages, limitations and uncertainties associated with the use of saliva as sample material.
This report presents the objectives, methods, results, and conclusions of a collaborative study called the 'European Listeria Typing Exercise’ (ELiTE), as well as recommendations for further studies.
A collaborative study between ECDC, the European Food Safety Authority (EFSA) and the European Union Reference Laboratory (EURL) for Listeria monocytogenes* found a relatively high degree of dissemination of certain listeriosis bacteria in the food chain and in the human population across the European Union (EU).
ECDC has mapped the detection and characterisation capability and capacity for SARS-CoV-2 variants across the EU/EEA. This is the fifth laboratory capacity survey since the beginning of the COVID-19 pandemic in December 2019.
This report assesses the current status of the EU/EEA and the UK COVID-19 laboratory response based on a short survey sent to all Member States and the UK.
This technical guidance aims to provide guidelines to laboratories and relevant stakeholders in the European Union (EU), European Economic Area (EEA) and other countries in the WHO European region in making decisions on establishing sequencing capacities and capabilities, in making decisions on which technologies to use and/or in deciding on the role of sequencing for SARS-CoV-2 diagnostics, research, outbreak investigations and surveillance.